Insider Selling: Sera Prognostics, Inc. (NASDAQ:SERA) CFO Sells 5,056 Shares of Stock

Sera Prognostics, Inc. (NASDAQ:SERA) CFO Austin Aerts sold 5,056 shares of the stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $7.57, for a total value of $38,273.92. Following the completion of the sale, the chief financial officer now directly owns 298,665 shares of the company’s stock, valued at $2,260,894.05. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Austin Aerts also recently made the following trade(s):

• On Wednesday, August 7th, Austin Aerts sold 6,760 shares of Sera Prognostics stock. The shares were sold at an average price of $7.42, for a total value of $50,159.20.

Sera Prognostics Trading Up 1.9 %

SERA stock opened at $7.54 on Thursday. The company has a market capitalization of $251.61 million, a P/E ratio of -7.05 and a beta of 1.03. Sera Prognostics, Inc. has a twelve month low of $1.56 and a twelve month high of $12.35. The business has a 50 day simple moving average of $7.22 and a 200-day simple moving average of $8.30.

Sera Prognostics (NASDAQ:SERA) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.02). Sera Prognostics had a negative return on equity of 46.71% and a negative net margin of 11,843.79%. The company had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.08 million. During the same quarter last year, the company earned ($0.34) EPS. Research analysts predict that Sera Prognostics, Inc. will post -0.95 EPS for the current fiscal year.

Institutional Investors Weigh In On Sera Prognostics

Large investors have recently modified their holdings of the stock. StepStone Group LP purchased a new stake in shares of Sera Prognostics during the fourth quarter worth approximately $61,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Sera Prognostics during the second quarter worth approximately $68,000. Sanders Morris Harris LLC purchased a new stake in shares of Sera Prognostics during the first quarter worth approximately $174,000. Lake Street Advisors Group LLC purchased a new stake in shares of Sera Prognostics during the second quarter worth approximately $144,000. Finally, American Century Companies Inc. raised its stake in shares of Sera Prognostics by 12.7% during the second quarter. American Century Companies Inc. now owns 25,682 shares of the company’s stock worth $152,000 after purchasing an additional 2,891 shares during the last quarter. Hedge funds and other institutional investors own 54.64% of the company’s stock.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.